Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,302,495
  • Shares Outstanding, K 118,017
  • Annual Sales, $ 1,397 M
  • Annual Income, $ 316,890 K
  • EBIT $ 594 M
  • EBITDA $ 687 M
  • 60-Month Beta 0.97
  • Price/Sales 5.95
  • Price/Cash Flow 14.75
  • Price/Book 169.50

Options Overview Details

View History
  • Implied Volatility 33.57% (+1.91%)
  • Historical Volatility 40.87%
  • IV Percentile 13%
  • IV Rank 14.03%
  • IV High 59.09% on 04/04/25
  • IV Low 29.41% on 06/16/25
  • Expected Move (DTE 22) 4.00 (5.77%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 439
  • Volume Avg (30-Day) 769
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 14,001
  • Open Int (30-Day) 13,247
  • Expected Range 65.23 to 73.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.55
  • Number of Estimates 4
  • High Estimate 1.70
  • Low Estimate 1.42
  • Prior Year 1.03
  • Growth Rate Est. (year over year) +50.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.38 +1.23%
on 02/26/26
82.22 -15.81%
on 02/09/26
-0.65 (-0.93%)
since 01/26/26
3-Month
61.22 +13.06%
on 12/11/25
82.22 -15.81%
on 02/09/26
-3.44 (-4.73%)
since 11/26/25
52-Week
47.50 +45.73%
on 05/14/25
82.22 -15.81%
on 02/09/26
+11.30 (+19.51%)
since 02/26/25

Most Recent Stories

More News
Halozyme to Participate in Upcoming Investor Conferences

SAN DIEGO , Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present...

HALO : 69.22 (-1.61%)
2 Reasons to Like HALO (and 1 Not So Much)

2 Reasons to Like HALO (and 1 Not So Much)

HALO : 69.22 (-1.61%)
Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales

HALO : 69.22 (-1.61%)
Halozyme Therapeutics: Q4 Earnings Snapshot

Halozyme Therapeutics: Q4 Earnings Snapshot

HALO : 69.22 (-1.61%)
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million

HALO : 69.22 (-1.61%)
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know

ACHC : 22.29 (+6.96%)
HIMS : 15.60 (-1.39%)
PRVA : 24.91 (+9.98%)
HALO : 69.22 (-1.61%)
RDNT : 72.09 (+2.97%)
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results

SAN DIEGO , Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results...

HALO : 69.22 (-1.61%)
3 Small-Cap Stocks with Solid Fundamentals

3 Small-Cap Stocks with Solid Fundamentals

AWI : 175.57 (+1.95%)
HALO : 69.22 (-1.61%)
WBTN : 11.56 (+2.48%)
3 Growth Stocks Set to Flourish

3 Growth Stocks Set to Flourish

ARES : 118.08 (-0.92%)
VRT : 259.23 (-1.13%)
HALO : 69.22 (-1.61%)
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance

Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of  $1,385 - $1,400 million, YoY Growth of 36% to 38% 1 - Royalty Revenue of $865 - $870...

HALO : 69.22 (-1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company...

See More

Key Turning Points

3rd Resistance Point 72.12
2nd Resistance Point 71.21
1st Resistance Point 70.21
Last Price 69.22
1st Support Level 68.30
2nd Support Level 67.39
3rd Support Level 66.39

See More

52-Week High 82.22
Last Price 69.22
Fibonacci 61.8% 68.96
Fibonacci 50% 64.86
Fibonacci 38.2% 60.76
52-Week Low 47.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar